Teza Capital Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 1,156.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 149,166 shares of the biopharmaceutical company's stock after buying an additional 137,293 shares during the period. Pfizer makes up about 0.6% of Teza Capital Management LLC's portfolio, making the stock its 28th largest position. Teza Capital Management LLC's holdings in Pfizer were worth $3,957,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at about $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter worth about $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer in the 4th quarter valued at about $27,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer during the 4th quarter worth approximately $28,000. Finally, Noble Wealth Management PBC purchased a new position in shares of Pfizer in the 4th quarter worth approximately $31,000. 68.36% of the stock is owned by institutional investors.
Pfizer Stock Performance
Pfizer stock traded up $0.51 during mid-day trading on Tuesday, reaching $23.51. The company's stock had a trading volume of 56,982,321 shares, compared to its average volume of 41,026,668. The firm's fifty day moving average price is $23.60 and its two-hundred day moving average price is $25.28. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a market capitalization of $133.66 billion, a P/E ratio of 16.67, a PEG ratio of 0.64 and a beta of 0.58.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.82 earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.32%. Pfizer's dividend payout ratio (DPR) is currently 124.64%.
Analysts Set New Price Targets
PFE has been the subject of a number of research analyst reports. UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and an average price target of $29.17.
Get Our Latest Report on Pfizer
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
